Home / Research / Regulatory news and changes SECTION 04 OF 12 / Monitor Regulatory news and changes Track dated changes and the actions they require.
17 Pages
56 Sources cited
18 Nov 2026 Last updated
THE CHANGE BOARD
What changed. Who acts next. All Confirmed Upcoming Proposed Undated
FDA confirmed
November 9, 2026 FDA requires GLP-1 labelling changes concerning a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION. Who should act: All clinical programmes and dispensing partners
IMMEDIATE ACTION Medical director: review counselling, escalation and partner materials. (fda.gov )
Read the research → FTC confirmed
November 10, 2026 FTC’s Hims & Hers case records an amended complaint; five additional states joined the privacy and billing litigation. These remain allegations, not adjudicated findings. Who should act: Telehealth platforms, subscription clinics and integrated access vendors
IMMEDIATE ACTION Compliance: review data sharing, charging triggers and cancellation workflows. (ftc.gov )
Read the research → HHS proposed
October 30, 2026 HHS publishes notice of a draft/interim enforcement-discretion policy for specified peptide substances—not a general GLP-1 compounding permission. Who should act: Clinics receiving peptide-expansion proposals
IMMEDIATE ACTION Counsel: reject extrapolation beyond the substances and conditions actually listed. (govinfo.gov )
Read the research → FDA confirmed
September 18, 2026 FDA’s Empower Pharmacy warning letter challenges apparently copied GLP-1 preparations and supporting patient-difference documentation. Who should act: Clinics relying on patient-specific compounding
IMMEDIATE ACTION Audit prescribing templates and evidence supporting formulation changes. (fda.gov )
Read the research → Fifth Circuit confirmed
August 27, 2026; semaglutide opinion revised September 1 Fifth Circuit opinions affirm judgments supporting FDA’s tirzepatide and semaglutide shortage decisions. Who should act: Buyers relying on litigation to preserve shortage-era supply
IMMEDIATE ACTION Require the actual order behind any claimed litigation protection. (ca5.uscourts.gov )
Read the research → FDA confirmed
August 12, 2026 FDA letter addresses compounded GLP-1 multidose-vial labelling, dosing confusion and use beyond the customary post-puncture period. Who should act: Clinical, procurement and finance teams
IMMEDIATE ACTION Reconcile vial size, discard instructions and usable supply before accepting quotes. (azbn.gov )
Read the research → Show all 14 entries → Confirmed denotes the occurrence of the dated event in the supplied research, not the adjudication of allegations or approval of a supply route. These remain allegations, not adjudicated findings.
Research quality self-assessment 9 / 10 buyer fit
9 / 10 depth
9 / 10 search terms
9 / 10 sources
The research’s own assessment; not an external rating.